StreetInsider.com News Articles

Form 4 CareDx, Inc. For: Jul 16 Filed by: Valantine Hannah

Fri, 17 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260717/26784633.html

Form 4 CareDx, Inc. For: Jul 16 Filed by: Valantine Hannah

Fri, 17 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260717/26784633.html

Form 4 CareDx, Inc. For: Jul 16 Filed by: Hanna John Walter JR

Fri, 17 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260717/26784645.html

Form 4 CareDx, Inc. For: Jul 16 Filed by: Hanna John Walter JR

Fri, 17 Jul 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260717/26784645.html

H.C. Wainwright Reiterates Neutral Rating on CareDx, Inc (CDNA)

Fri, 17 Jul 2026 07:09:22 -0400

H.C. Wainwright analyst Yi Chen reiterated a Neutral rating on CareDx, Inc (NASDAQ: CDNA).

The analyst commented: "Yesterday, CareDx announced the finalization of the Medicare Local Coverage Determination (LCD) process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across CareDx’s transplant surveillance offerings in kidney, heart, and lung. For kidney, the policy affirms coverage of AlloSure Kidney for surveillance testing for up to six tests in the first-year post-transplant and for up to four tests per year in years two and three. For heart, coverage is maintained for AlloMap and AlloSure Heart, including use of

Form 144 CareDx, Inc. Filed by: Hanna John Walter JR

Thu, 16 Jul 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260716/26780145.html

Form 144 CareDx, Inc. Filed by: Hanna John Walter JR

Thu, 16 Jul 2026 16:35:00 -0400

si-local-file:///var/storage/secattach/20260716/26780145.html

Form 144 CareDx, Inc. Filed by: Valantine Hannah

Thu, 16 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260716/26780123.html

Form 144 CareDx, Inc. Filed by: Valantine Hannah

Thu, 16 Jul 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260716/26780123.html

CareDx, Inc (CDNA) PT Raised to $45 at BTIG

Thu, 16 Jul 2026 13:11:01 -0400

(Updated - July 16, 2026 1:11 PM EDT)

BTIG analyst Sung Ji Nam raised the price target on CareDx, Inc (NASDAQ: CDNA) to $45.00 (from $28.00) while maintaining a Buy rating.

The analyst commented: "Shares of CDNA are up 25% after Palmetto GBA (MolDx) issued a final LCD for solid organ transplant molecular testing. The final LCD came in better than what was feared from the draft proposal, and affirms coverage across kidney, heart, and lung surveillance testing with what we view as generous limits well above where CDNA is doing today. The combination of AlloMap + AlloSure (HeartCare), which was called

CareDx, Inc (CDNA) PT Raised to $45 at BTIG

Thu, 16 Jul 2026 13:11:01 -0400

(Updated - July 16, 2026 1:11 PM EDT)

BTIG analyst Sung Ji Nam raised the price target on CareDx, Inc (NASDAQ: CDNA) to $45.00 (from $28.00) while maintaining a Buy rating.

CareDx, Inc (CDNA) PT Raised to $35 at Craig-Hallum

Thu, 16 Jul 2026 09:58:03 -0400

Craig-Hallum analyst Bill Bonello raised the price target on CareDx, Inc (NASDAQ: CDNA) to $35.00 while maintaining a Buy rating.

Medicare finalizes coverage for CareDx transplant molecular tests

Thu, 16 Jul 2026 08:38:54 -0400

CareDx, Inc. (Nasdaq: CDNA) announced that Medicare has finalized a Local Coverage Determination (LCD) affirming coverage of its molecular surveillance tests for kidney, heart, and lung transplant patients.

The Final LCD was published on July 16, 2026, and is expected to take effect on August 30, 2026. A draft LCD had been released on July 17, 2025, and was open for public comment through August 31, 2025.

Under the finalized policy, CareDx's AlloSure Kidney test is covered for up to six surveillance tests in the first year post-transplant and up to four tests per year in years two and three. The company

CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

Thu, 16 Jul 2026 08:35:00 -0400

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced it will report financial results for the second quarter 2026 after market close on Thursday, July 30, 2026. The Company will host a webcast and conference call that day at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the conference call can be accessed on the Events & Presentations section of CareDx’s Investor Relations website at investors.caredx.com. To participate in the live conference call via telephone,

CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

Thu, 16 Jul 2026 08:35:00 -0400

CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

Thu, 16 Jul 2026 08:35:00 -0400

CareDx to Report Second Quarter 2026 Financial Results on July 30, 2026

Thu, 16 Jul 2026 08:35:00 -0400

CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

Thu, 16 Jul 2026 08:30:00 -0400

Coverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine diagnostics company in transplant, specialty oncology, and cell therapy, today announced the finalization of the Medicare Local Coverage Determination (LCD) process related to molecular testing for solid organ allograft rejection. The final policy affirms coverage across CareDx’s transplant surveillance offerings in kidney, heart, and lung.

Kidney: The policy affirms coverage of AlloSure® Kidney for surveillance testing for up to six tests in the first-year post-transplant and for up to four tests per

CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

Thu, 16 Jul 2026 08:30:00 -0400

Coverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung

Kidney: The policy affirms coverage of AlloSure® Kidney for surveillance testing for up to six tests in the first-year post-transplant and for up to four tests per

CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

Thu, 16 Jul 2026 08:30:00 -0400

Coverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung

Kidney: The policy affirms coverage of AlloSure® Kidney for surveillance testing for up to six tests in the first-year post-transplant and for up to four tests per

CareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determination

Thu, 16 Jul 2026 08:30:00 -0400

Coverage for Surveillance Testing Affirmed for Early Detection of Allograft Rejection in Kidney, Heart, and Lung

Kidney: The policy affirms coverage of AlloSure® Kidney for surveillance testing for up to six tests in the first-year post-transplant and for up to four tests per

Form 4 CareDx, Inc. For: Jul 02 Filed by: Goldberg Michael

Tue, 07 Jul 2026 17:54:00 -0400

si-local-file:///var/storage/secattach/20260707/26742900.html

Form 4 CareDx, Inc. For: Jul 02 Filed by: Goldberg Michael

Tue, 07 Jul 2026 17:54:00 -0400

si-local-file:///var/storage/secattach/20260707/26742900.html

Form 8-K CareDx, Inc. For: Jun 30

Tue, 07 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260707/26742664.html

Form 8-K CareDx, Inc. For: Jun 30

Tue, 07 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260707/26742664.html